Despite the major impact of GLP-1 receptor agonists on weight management, post-discontinuation rebound remains a significant hurdle, as these systemic therapies deflate fat cells rather than eliminate them. An emerging injectable candidate, CBL-514, approaches the problem through targeted adipocyte clearance. Rather than temporarily shrinking lipid volume, the compound selectively triggers apoptosis (programmed cell death) in fat cells while sparing adjacent muscle and nerve tissues.

As ScienceDaily reports, early clinical results presented at the European Association for the Study of Diabetes (EASD) showed that CBL-514 reduced targeted fat deposits by more than 10%. Because the destroyed fat cells cannot simply refill once treatment ends, researchers hypothesize that this permanent cellular reduction could mitigate the rapid weight regain typically observed after discontinuing drugs like Wegovy and Zepbound.

What is visceral fat?

Visceral fat, or visceral adipose tissue (VAT), is a metabolically active fat stored deep within the abdominal cavity, wrapping around vital organs like the liver, pancreas, kidneys and intestines.

Unlike subcutaneous fat – which sits directly beneath the skin, can be pinched, and functions primarily as energy storage and insulation – visceral fat operates as an active endocrine organ. It continuously secretes pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).

“Chronic systemic inflammation and excessive accumulation of visceral fat are directly linked to non-alcoholic fatty liver disease – now termed metabolic dysfunction-associated steatotic liver disease (MASLD),” explains Dr. Justus Rabach, MD. “This accumulation significantly elevates the risk of hypertension, dyslipidemia, type 2 diabetes, heart attack and stroke.”

What makes visceral fat uniquely hazardous compared to fat around the hips or thighs is its direct access to the liver. Visceral depots drain fatty acids and inflammatory chemicals straight into the hepatic portal vein, overloading hepatic metabolism and triggering downstream systemic disease.

How CBL-514 works

Unlike systemic GLP-1 and GIP receptor agonists, which act centrally in the brain to suppress appetite, CBL-514 is a targeted, small-molecule injectable designed to permanently eliminate adipocytes locally. Administered subcutaneously, the compound selectively induces the intrinsic pathway of apoptosis (programmed cell death) in fat-storing cells while sparing adjacent fibroblasts, vascular endothelial cells and peripheral nerves.

This apoptotic mechanism is critical: unlike necrotic agents that rupture cell membranes and trigger severe local inflammation, CBL-514 causes targeted adipocytes to condense and fragment internally while preserving the outer membranes. Over the following weeks, scavenger macrophages clear cellular remnants via phagocytosis, thereby permanently reducing the regional fat-cell depot without collateral tissue damage.

While developed primarily for localized subcutaneous fat reduction, recent exploratory data suggest broader metabolic potential. In a Phase 2 trial led by researchers at the University of Alabama at Birmingham and developer Caliway Biopharmaceuticals, MRI analysis revealed that patients receiving subcutaneous CBL-514 also achieved an average 12.01% reduction in deep visceral fat volume at four weeks post-treatment – an effect sustained through week 12, whereas the placebo group gained visceral fat.

Common side effects

The most commonly reported adverse reactions to CBL-514 are localized, self-limited tissue reactions following percutaneous injection into the abdominal fat pad, not gastrointestinal upset.

Safety registries from phase 2 clinical trials showed that adverse reactions were mostly mild to moderate and did not require treatment.

Local tenderness, mild pain and transient swelling at the injection sites were the most common side effects among patients receiving the active compound, peaking in the first few days after injection and subsiding as macrophages cleared apoptotic cells.

Frequent transient erythema (redness) and slight, superficial, subcutaneous bruising occurred along the needle tracks in all treatment groups, as expected in normal dermatological and cosmetic injections.

Rare or serious side effects

In the early phase 2 clinical trials (CBL-0204 and CBL-0205), no drug-related adverse events or any systemic organ toxicities were reported in human subjects treated up to 600 mg.

But clinical toxicologists and endocrinologists warn that several theoretical safety issues should be assessed in larger, long-term phase 3 trials: There is a theoretical concern about systemic lipid surges with simultaneous destruction of large numbers of adipocytes, especially if free fatty acids and glycerol from lipid breakdown can enter the circulation, necessitating measurement of serum triglycerides and liver enzymes.

If the abdominal fat layer is not evenly treated with injections, skin contour irregularities or asymmetrical subcutaneous depressions may result. Damage to fat cells can cause inflammation in the area, which is another concern in secondary inflammatory panniculitis.

Long-term metabolic adaptation in humans is unknown, and whether the capacity to store fat in the abdomen is impaired and leads to ectopic fat deposition in the liver, heart or skeletal muscle upon a return to a high-calorie diet is also unknown.

Is CBL-514 available for purchase?

No, CBL-514 is a purely experimental drug that is not yet commercially available, medically prescribed, or for use at med-spas anywhere in the world.

The compound is in active clinical development by Caliway Biopharmaceuticals. It is not marketing-approved or cleared by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other international regulatory agency.

Two critical, randomized, double-blind, placebo-controlled phase 3 clinical trials are actively recruiting to confirm the compound’s safety, best-in-class dosage, and long-term effectiveness in larger demographic groups. There are still a few years before it completes the regulatory process and becomes commercially available. Consumers should be wary of unregulated online vendors or websites that claim to sell authentic or safe versions of the compound.

Alternatives

Patients can still safely and effectively reduce harmful visceral fat through a combination of evidence-based lifestyle changes and legally approved medical treatments while awaiting the results of a clinical trial of targeted fat-apoptosis injections.

While an expensive MRI scan is not necessary, it is possible to determine if you have extra visceral fat. Measure your waist at the belly button and your hip at the widest point, then divide your waist by your hip; a ratio > 0.85 in women or > 0.90 in men indicates greater visceral fat accumulation and higher cardiometabolic risk.

Aerobic exercise plus high-intensity interval training (HIIT) is the strongest non-drug trigger for burning belly fat. Visceral fat has more beta-adrenergic receptors and blood flow, which is why it is more sensitive to the effects of brisk walking, running, swimming and cycling, which release beta-adrenergic receptors.

These two drugs, semaglutide (Wegovy) and tirzepatide (Zepbound), are GLP-1 receptor agonists and GIP/GLP-1 receptor agonists, respectively, that have been approved for general use and have been shown to provide substantial loss of overall body weight and visceral fat volume via appetite suppression and insulin sensitivity, but without adipocyte destruction.

For individuals with severe obesity who qualify for a surgical procedure, bariatric surgery can result in dramatic and lasting decreases in visceral adiposity and rapid remission of type 2 diabetes.

Dietary optimization, based on high-fiber whole foods, lean proteins, and avoiding refined sugars and trans fats, curbs systemic insulin spikes and enables the liver and abdominal organs to burn visceral fat for basic energy.

“My bottom-line message on this one is, if you have an elevated BMI, you’re trying to lose weight, you’ve tried a healthy diet, you’ve tried to exercise, and you’re not winning that fight, consider GLP-1s, and you’re going to get a secondary benefit,” advises Dr. Loren Rourke, M.D., MHCM, FACS, a Texas-based board-certified breast cancer surgeon.

Bottom line

In human phase 2 clinical trials, cerebral blood flow has increased by 10% or more after just half an hour of CBL-514 infusion. This promising injectable experimental drug selectively induces adipocyte death, eliminating pinchable subcutaneous fat and dangerous internal visceral fat by more than 10%. The therapy may also help to fight against the rebound weight gain, which is often seen after people stop taking GLP-1 drugs such as Wegovy and Zepbound. Although the treatment is still in phase 3 clinical development and not available for purchase, the currently approved medical therapies, high-fiber nutrition and sustained aerobic exercise remain effective and proven methods for removing dangerous visceral belly fat.

Frequently Asked Questions

What is the #1 habit you should start to lose visceral fat?

Engaging in regular aerobic cardiovascular exercise, such as brisk walking, jogging, cycling, or swimming, for at least 30 minutes, five days per week, is the single most effective daily habit for mobilizing and burning deep visceral belly fat.

What are the worst foods for visceral fat?

The worst foods for visceral fat accumulation are sugar-sweetened beverages (sodas, sweet teas and fruit juices) and ultra-processed foods rich in trans fats, refined white flour, and high-fructose corn syrup, all of which rapidly spike insulin levels and promote abdominal fat storage around internal organs.

Citations

Science Daily. New injection makes fat cells self-destruct. ScienceDaily. 2026. https://www.sciencedaily.com/releases/2026/10/261008102713.htm

Habibullah M, Jemmieh K, Ouda A, Haider MZ, Malki MI, Elzouki AN. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Frontiers in Medicine. 2024;11. doi:10.3389/fmed.2024.1291501

Gold M, Schlessinger J, Goodman GJ, et al. Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study. Aesthet Surg J. 2025;45(6):611-620. doi:10.1093/asj/sjaf032

Caliway Biopharma. EASD Press Room Features New Data on CBL-514 for Reducing Subcutaneous and Visceral Fat-Caliway Biopharmaceuticals Co., Ltd. Caliway Biopharmaceuticals Co., Ltd. 2026. https://www.caliwaybiopharma.com/en/news-detail/-CBL-514-EASD-2026-subcutaneousfat-visceralfat-reduction-study-ENG/